Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS, Inc. (NYSE American: DSS) generates news across a wide range of sectors, reflecting its role as a multinational company with diversified business lines in packaging, biohealth innovation, financial services, alternative trading, and real estate. The company’s press releases and regulatory disclosures highlight strategic transactions, capital markets developments, operational milestones, and portfolio optimization efforts.
News about DSS often covers corporate strategy and portfolio management, including spin-offs, asset sales, and transactions involving key subsidiaries. Examples include the sale of the Celios air purification asset to Impact BioMedical Inc., as well as a definitive merger agreement under which Impact BioMedical will be acquired through a reverse merger with Dr. Ashleys Limited, resulting in a new public company. These items illustrate DSS’s stated approach of unlocking value by advancing subsidiaries toward independent public listings and other exit opportunities.
Investors and followers of DSS can also expect updates on financial performance and corporate actions. The company reports on revenue trends, cash flow improvements, debt reduction, and asset monetization, such as the sale of a real estate facility and growth in rental income. Leadership communications, including letters to shareholders and announcements of executive appointments, provide additional context on strategic priorities, cost reduction initiatives, and the focus on core growth verticals.
Because DSS has subsidiaries in securities and investment management, its news flow includes developments at entities like Sentinel Brokers Company, Inc. and AmericaFirst Funds. These updates may involve regulatory approvals, such as FINRA authorization for underwriting activities, changes to mutual fund boards, and expansion of capital markets capabilities. For a comprehensive view of DSS-related developments, readers can use this news page to follow corporate strategy, subsidiary activity, and key financial and regulatory events over time.
On October 19, 2022, DSS announced that its subsidiary, Impact BioMedical, will be featured in a documentary titled "The BioQuest". The film highlights GRDG Sciences' innovative research and technologies aimed at solving global health issues. GRDG's recent projects, including the multi-year Sombrero initiative, have led to several breakthrough technologies such as Equivir and antimicrobial bioplastics. The documentary, produced by Diamond Studios, begins filming on December 3, 2022, with aims to present GRDG's mission of creating impactful health solutions.
DSS, Inc. (NYSE American: DSS) announced on August 30, 2022, that it received a notice for non-compliance with NYSE American's listing requirements due to its inability to timely file the Form 10-Q. The company has a possible 12 months to rectify this issue, with an initial automatic six-month period. DSS cited challenges that prevented the timely filing and is actively working to resolve these issues. With a diversified portfolio across various sectors, DSS aims to drive profitability and shareholder value despite these reporting delays.
DSS announced a significant advancement in biotechnology with the development of a Quantum-based antihistamine by its subsidiary, Impact Biomedical, and research partner, GRDG. This new compound could be up to 50 times more effective than existing drugs, offering lower toxicity through reduced dosages. The initiative aims to tackle the looming patent cliff in the pharmaceutical industry, where over $200 billion in revenue is at risk from 2025-2030 due to expiring patents. The Quantum Project may positively reshape drug development and holds potential for global health improvements.
On July 21, 2022, DSS announced that its subsidiary Global BioLife entered a licensing agreement with ProPhase BioPharma for the Linebacker portfolio, consisting of patented small molecule PIM kinase inhibitors. This agreement marks a significant milestone for Impact BioMedical and aims at further development in oncology, with ProPhase's CEO highlighting multi-billion-dollar potential. Pre-clinical testing indicates Linebacker could effectively cross the blood-brain barrier and tackle various diseases, including cancer.
DSS, a multinational company, announced the appointment of two independent directors to its Board: Frankie Wong and Joanne Wong Hiu Pan. Frankie Wong brings over 20 years of experience in financial reporting and has served in CFO roles at various listed companies. Joanne Wong has over 15 years in the financial industry as an investment manager. CEO Frank D. Heuszel stated that their addition enhances the board's expertise in legal, operations, financing, and more, supporting DSS's vision across its nine business divisions.
Impact Biomedical, a subsidiary of DSS, has signed a license agreement with ProPhase Labs for Equivir, a treatment aimed at reducing the occurrence and severity of viral outbreaks. With human clinical trials set to commence soon, Equivir, which has received two U.S. patents, is believed to block viral entry into host cells. The partnership leverages ProPhase's extensive experience in health product distribution, potentially expediting Equivir's market entry. The treatment may combat various viruses, including influenza and SARS-CoV-2, addressing critical global health needs.
DSS, Inc. announced that its subsidiary, Global BioLife, received a patent in China for its innovative mosquito repellant technology, 3F™. This formulation utilizes botanical oils to incapacitate mosquito receptors, enhancing its effectiveness over traditional repellants. The global mosquito repellant market is projected to grow from $6.9 billion in 2021 to $10.9 billion by 2028, with China recognized as a leading market. Frank Heuszel, President of Impact BioMedical, emphasized the technology's potential for licensing and commercialization, which could drive shareholder value.
DSS, Inc. (NYSE American: DSS) announced an upcoming interview with COO Jason Grady on The RedChip Money Report, airing on Bloomberg U.S. on May 7 at 7 p.m. ET. The show provides insights into small cap investing and features executives from public companies. DSS operates nine business divisions, focusing on strategic acquisitions and IPO spinoffs to enhance shareholder value. The company's diversified portfolio aims to drive profitability in high-growth sectors.
Impact Biomedical, a subsidiary of DSS, announced a positive report on its compound Equivir's international patentability for treating viral infections. The Patentability Report from WIPO indicated no prior art blocking patent claims for Equivir, which may limit viral outbreaks. This marks the third positive step for Equivir, following two U.S. patents awarded for its efficacy against influenza, Ebola, and rhinovirus. Equivir operates by blocking viruses from entering host cells and has potential applications against multiple viral infections, including SARS COV2.
DSS, Inc. (NYSE American: DSS) announced a transformative year ahead, supported by a substantial restructuring since late 2019. The firm boasts over $219 million in assets, including $69 million in cash. Aiming for a breakout year, DSS plans to acquire True Partner Capital, enhancing its global securities business. Recent public offerings generated over $121 million, aiding in strategic medical real estate acquisitions with yields around 8%. DSS expresses optimism about significant growth and potential IPOs in 2022, reflecting the company’s diverse portfolio and commitment to shareholder value.